Kanamycin A

Kanamycin A

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Kanamycin A
Category Antibiotics
Catalog number BBF-01884
CAS 59-01-8
Molecular Weight 484.50
Molecular Formula C18H36N4O11
Purity 95%

Online Inquiry

Description

Kanamycin is an aminoglycoside antibiotic that has inhibitory effects on gram-positive and negative bacteria and mycoplasma. It can be used for the prevention and treatment of chicken pullorum, colibacillosis, enteritis and other diseases, and has a significant effect on systemic sepsis, respiratory tract infection, peritonitis, etc. caused by drug-resistant bacteria.

Specification

Related CAS 64013-70-3 (disulfate) 25389-94-0 (sulfate)
Synonyms Amikacin EP Impurity D; O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy-α-D-glucopyranosyl-(1→4)]-2-deoxy-D-streptamine; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'-diamino-3,6'-dideoxydi-α-D-glucoside; KM; Kanacin; Kanamycin; 6-O-(3-amino-3-deoxy-a-D-glucopyranosyl)-4-O-(6-amino-6-deoxy-a-D-glucopyranosyl)-2-deoxy-D-streptamine
Storage Store at -20°C
IUPAC Name (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
Canonical SMILES C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N
InChI InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
InChI Key SBUJHOSQTJFQJX-NOAMYHISSA-N

Properties

Appearance White to Off-White Solid
Application Anti-bacterial agents; protein synthesis inhibitors
Antibiotic Activity Spectrum Gram-positive bacteria; Gram-negative bacteria; mycobacteria
Boiling Point 809.5°C at 760 mmHg
Melting Point >175°C (dec.)
Density 1.62 g/cm3
Solubility Soluble in Methanol (Slightly, Sonicated), Water (Slightly)

Reference Reading

1. Pharmacokinetics of amikacin in intensive care unit patients
de Gatta, M.F., Mendez, M.E., Romano, S., Calvo, M.V., Dominguez-Gil, A. and Lanao, J.M., 1996. Journal of clinical pharmacy and therapeutics, 21(6), pp.417-421.
To characterize the population pharmacokinetics of amikacin in intensive care unit (ICU) patients and to analyse whether these patients show different kinetic behaviour on the basis of their clinical diagnoses.
2. Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia
Amikin, A., Rocephin, C. and Fortaz, C., 1993. Ann Intern Med, 119, pp.584-593.
To compare the efficacy and toxicity of single daily dosing of amikacin and ceftriaxone with that of multiple daily dosing of amikacin and ceftazidime for febrile episodes in patients with cancer and granulocytopenia.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket